Phase II Study of 506U78 (NSC #686673) [nelarabine] in Patients With Previously Treated Cutaneous T-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Nelarabine (Primary)
- Indications T cell lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Sep 2005 New trial record.